


## Amendments to the Claims:

1. (Original) A compound having the formula:



wherein:

R<sub>1</sub> represents a radical selected from the group consisting of alkoxy, alkoxyalkyl, halogen, nitro, carboxy, carboxyalkyl, carbalkoxy, carbalkoxyalkyl, carboxamide, carboxamidoalkyl, alkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, sulfonamide, amidino, cyano, amino, amido, alkylamino, dialkylamino, alkylaminoalkyl, and alkoxy monosubstituted with a substituent selected from the group consisting of carboxy, amino, alkylamino and dialkylamino; and pharmaceutically acceptable salts of said compound.

2. (Original) A compound according to claim 1, selected from the group consisting of:

2,2'-[(3-Propylphenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[[3-Dimethylamino]phenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[[3-(Methylethyl)phenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[(3-Methylphenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[(3-Methoxyphenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[(3-Ethoxyphenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[(3-Chlorophenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[(3-Bromophenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-(2-Ethylbutyl)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-(2-Cyclohexyl)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[(3-Butylphenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[(3-Fluorophenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[(3-Pentylphenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-(1-Methylpropyl)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-(2-Methylpropyl)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-(3-Methoxyethyl)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[(3-Ethylphenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-(3-Ethyl(methylethyl)amino)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-(3-Ethylpropylamino)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[[(3-Diethylamino)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]]phenol];

2,2'-[[[(3-Butylethylamino)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]]phenol];

2,2'-[[[(3-Methylamino)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]]phenol];

3-[[Bis[[[5-(5-methyl-1H-tetrazol-1-yl)imino]methyl]-2-hydroxyphenyl]methylene]-N,N-diethylbenzenesulfonamide;

2,2'-[[[3-(2-Dimethylaminoethoxy)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]]phenol];

N-[[[3-[Bis[[[5-(5-methyl-1H-tetrazol-1-yl)imino]methyl]-2-hydroxyphenyl]methylene]phenyl]-2,2-dimethylpropanamide];

N-[[[3-[Bis[[[5-(5-methyl-1H-tetrazol-1-yl)imino]methyl]-2-hydroxyphenyl]methylene]phenyl]butanesulfonamide];

2,2'-[[[(3-Nitrophenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]]phenol];

2,2'-[[[(3-Methylthiophenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]]phenol];

2,2'-[[[(3-Methylsulfinylphenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]]phenol];

2,2'-[[[(3-Methylsulfonylphenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]]phenol];

3-[[Bis[[[5-(5-methyl-1H-tetrazol-1-yl)imino]methyl]-2-hydroxyphenyl]methylene]-N,N-dimethylbenzenesulfonamide;

2,2'-[[[3-(Propylaminophenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]]phenol];

2,2'-[[[3-[2-(Diethylaminopropoxy)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]]phenol];

N-[[[3-[Bis[[[5-(5-methyl-1H-tetrazol-1-yl)imino]methyl]-2-hydroxyphenyl]methylene]phenyl]acetamide];

N-[[[3-[Bis[[5-(5-methyl-1H-tetrazol-1-yl)imino]methyl]-2-hydroxyphenyl]methylene]phenyl]-N-propylacetamide;

N-[[[3-[Bis[[5-(5-methyl-1H-tetrazol-1-yl)imino]methyl]-2-hydroxyphenyl]methylene]phenyl]-N-(methylethyl)acetamide;

N-[[[3-[Bis[[5-(5-methyl-1H-tetrazol-1-yl)imino]methyl]-2-hydroxyphenyl]methylene]phenyl]-3-methyl-N-propylbutanamide;

N-[[[3-[Bis[[5-(5-methyl-1H-tetrazol-1-yl)imino]methyl]-2-hydroxyphenyl]methylene]phenyl]-3-methyl-N-(methylethyl)butanamide;

N-[[[3-[Bis[[5-(5-methyl-1H-tetrazol-1-yl)imino]methyl]-2-hydroxyphenyl]methylene]phenyl]-3-methyl-N-methylbutanamide;

N-[[[3-[Bis[[5-(5-methyl-1H-tetrazol-1-yl)imino]methyl]-2-hydroxyphenyl]methylene]phenyl]-N-ethylacetamide;

N-[[[3-[Bis[[5-(5-methyl-1H-tetrazol-1-yl)imino]methyl]-2-hydroxyphenyl]methylene]phenyl]propane sulfonamide; and

2,2'-[[[3-Methyl(methylethyl)aminophenyl]methylene]bis[4-[[[5-methyl-1H-tetrazol-1-yl)imino]methyl]]]phenol.

3. (Original) The compound according to claim 1 selected from the group consisting of:

2,2'-[(3-Propylphenyl)methylene]bis[4-[[[5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol,

2,2'-[[[3-(Dimethylamino)phenyl]methylene]bis[4-[[[5-methyl-1H-tetrazol-1-yl)imino]methyl]]]phenol,

2,2'-[[[3-(Methylethyl)phenyl]methylene]bis[4-[[[5-methyl-1H-tetrazol-1-yl)imino]methyl]]]phenol,

2,2'-[[[3-(Methoxyethyl)phenyl]methylene]bis[4-[[[5-methyl-1H-tetrazol-1-yl)imino]methyl]]]phenol,

2,2'-[[[3-Ethyl(methylethyl)amino]phenyl]methylene]bis[4-[[[5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol, and

2,2'-[[[3-Diethylamino]phenyl]methylene]bis[4-[[[5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol.

4. (Original) The compound according to claim 1 having the name 2,2'-[(3-Propylphenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol.
5. (Withdrawn) The compound according to claim 1 having the name 2,2'-[[[(3-Dimethylamino)phenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol.
6. (Withdrawn) The compound according to claim 1 having the name 2,2'-[[3-(Methyl)phenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol.
7. (Withdrawn) The compound according to claim 1 having the name 2,2'-[[[3-Methoxyethyl)phenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol.
8. (Withdrawn) The compound according to claim 1 having the name 2,2'-[[[3-Ethyl(methylethyl)amino]phenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol.
9. (Withdrawn) The compound according to claim 1 having the name 2,2'-[[[3-Diethylamino)phenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol.
10. (Withdrawn) The compound according to claim 1 having the name 2,2'-[[[3-Ethylpropylamino)phenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol.
11. (Currently Amended) A pharmaceutical composition for treating ~~or preventing~~ pneumovirus infection, said composition comprising a compound according to claim 1 in an amount ~~effect~~ to attenuate infectivity of said virus, and a pharmaceutically acceptable carrier medium.
12. (Original) A pharmaceutical composition according to claim 11, further comprising at least one supplemental active agent selected from the group consisting of intererons, ribavirin and immunomodulators, immunoglobulins, anti-inflammatory agents,

antibiotics, anti-virals and anti-infectives.

13. (Original) A pharmaceutical composition according to claim 11, wherein said pharmaceutical composition comprises ethanol.

14. (Original) A pharmaceutical composition according to claim 11, wherein said pharmaceutical composition comprises propylene glycol.

15. (Original) A pharmaceutical composition according to claim 11, wherein said pharmaceutical composition comprises water.

16. (Original) A pharmaceutical composition according to claim 13, wherein said pharmaceutical composition comprises at least 50% ethanol.

17. (Original) A pharmaceutical composition according to claim 13, wherein said pharmaceutical composition comprises at least 60% ethanol.

18. (Original) A pharmaceutical composition according to claim 13, wherein said pharmaceutical composition comprises at least 70% ethanol.

19. (Original) A pharmaceutical composition according to claim 13, wherein said pharmaceutical composition comprises at least 80% ethanol.

20. (Original) A pharmaceutical composition according to claim 13, wherein said pharmaceutical composition comprises at least 90% ethanol.

21. (Original) A pharmaceutical composition according to claim 13, wherein said pharmaceutically acceptable carrier medium comprises ethanol, water, and propylene glycol.

22. (Original) A pharmaceutical composition according to claim 13, wherein said pharmaceutical composition comprises about 85% ethanol, about 10% propylene glycol, and about 5% water.

23. (Original) A pharmaceutical composition according to claim 21, wherein said pharmaceutical composition comprises less than 5% water.
24. (Withdrawn) A method of treatment of pneumovirus infection in a patient in need of said treatment, said method comprising administering to said patient a therapeutically effective amount of a compound according to claim 1.
25. (Withdrawn) A method according to claim 24, wherein said compound is administered through inhalation.
26. (Withdrawn) A method according to claim 24, wherein said compound is administered by an electrostatic delivery
27. (Withdrawn) A method according to claim 26, wherein said electrostatic delivery device is hand-held.
28. (Withdrawn) A method as according to claim 26, wherein said electrostatic delivery device is disposable.
29. (Withdrawn) A method according to claim 26, wherein said electrostatic delivery device is for a single user.
30. (Withdrawn) A method according to claim 26, wherein said electrostatic delivery device comprises a removable mouthpiece.
31. (Withdrawn) A method according to claim 26, wherein said electrostatic delivery device comprises a mask.
32. (Withdrawn) A method of treating cells in culture that are susceptible to infection by, or infected or contaminated with a pneumovirus, said method comprising administering to said cultures an effective amount of a compound according to claim 1.
33. (Original) A method of treating biological materials that are susceptible to

infection by, or infected or contaminated with a pneumovirus, said method comprising administering to said materials an effective amount of a compound according to claim 1.

34. (Cancelled)

35. (Cancelled)